Entry inhibitor-based microbicides are active in vitro against HIV-1 isolates from multiple genetic subtypes.
暂无分享,去创建一个
John P. Moore | T. Ketas | Min Lu | P. Klasse | V. Polonis | Susan M. Schader | J. Zurita | Esther Teo
[1] P. Kilmarx,et al. Global epidemiology of HIV , 2009, Current opinion in HIV and AIDS.
[2] John P. Moore,et al. Protein design of a bacterially expressed HIV-1 gp41 fusion inhibitor. , 2007, Biochemistry.
[3] M. McElrath,et al. Initial Events in Establishing Vaginal Entry and Infection by Human Immunodeficiency Virus Type-1 , 2007, Immunity.
[4] John P. Moore,et al. Which Topical Microbicides for Blocking HIV-1 Transmission Will Work in the Real World? , 2006, PLoS medicine.
[5] Hong Lu,et al. Cellulose acetate 1,2-benzenedicarboxylate inhibits infection by cell-free and cell-associated primary HIV-1 isolates. , 2006, AIDS research and human retroviruses.
[6] M. Lederman,et al. Microbicides and other topical strategies to prevent vaginal transmission of HIV , 2006, Nature Reviews Immunology.
[7] Robin Shattock,et al. Selective transmission of CCR5-utilizing HIV-1: the 'gatekeeper' problem resolved? , 2006, Nature Reviews Microbiology.
[8] P. Klasse,et al. How Do Viral and Host Factors Modulate the Sexual Transmission of HIV? Can Transmission Be Blocked? , 2006, PLoS medicine.
[9] John P. Moore,et al. Protection of macaques from vaginal SHIV challenge by vaginally delivered inhibitors of virus–cell fusion , 2005, Nature.
[10] M. Hirsch,et al. TAK-652, a Novel CCR5 Inhibitor, has Favourable Drug Interactions with other Antiretrovirals in Vitro , 2005, Antiviral therapy.
[11] P. Clapham,et al. Inhibition of CCR5-mediated infection by diverse R5 and R5X4 HIV and SIV isolates using novel small molecule inhibitors of CCR5: effects of viral diversity, target cell and receptor density. , 2005, Antiviral research.
[12] A. Haase. Perils at mucosal front lines for HIV and SIV and their hosts , 2005, Nature Reviews Immunology.
[13] Dominique Schols,et al. AMD3465, a monomacrocyclic CXCR4 antagonist and potent HIV entry inhibitor. , 2005, Biochemical pharmacology.
[14] Lynn Morris,et al. Recommendations for the Design and Use of Standard Virus Panels To Assess Neutralizing Antibody Responses Elicited by Candidate Human Immunodeficiency Virus Type 1 Vaccines , 2005, Journal of Virology.
[15] Xiping Wei,et al. Human Immunodeficiency Virus Type 1 env Clones from Acute and Early Subtype B Infections for Standardized Assessments of Vaccine-Elicited Neutralizing Antibodies , 2005, Journal of Virology.
[16] M. Hirsch,et al. TAK-220, a Novel Small-Molecule CCR5 Antagonist, Has Favorable Anti-Human Immunodeficiency Virus Interactions with Other Antiretrovirals In Vitro , 2005, Antimicrobial Agents and Chemotherapy.
[17] P. Harrigan,et al. Molecular and clinical epidemiology of CXCR4-using HIV-1 in a large population of antiretroviral-naive individuals. , 2005, The Journal of infectious diseases.
[18] A. Trkola,et al. Virus Isolates during Acute and Chronic Human Immunodeficiency Virus Type 1 Infection Show Distinct Patterns of Sensitivity to Entry Inhibitors , 2005, Journal of Virology.
[19] Eun-Young Kim,et al. Propagation and Dissemination of Infection after Vaginal Transmission of Simian Immunodeficiency Virus , 2005, Journal of Virology.
[20] E. Sanders-Buell,et al. Biologic and Genetic Characterization of a Panel of 60 Human Immunodeficiency Virus Type 1 Isolates, Representing Clades A, B, C, D, CRF01_AE, and CRF02_AG, for the Development and Assessment of Candidate Vaccines , 2005, Journal of Virology.
[21] B. Gazzard,et al. Epidemiology and predictive factors for chemokine receptor use in HIV-1 infection. , 2005, The Journal of infectious diseases.
[22] Ronald G. Collman,et al. Preferential Use of CXCR4 by R5X4 Human Immunodeficiency Virus Type 1 Isolates for Infection of Primary Lymphocytes , 2005, Journal of Virology.
[23] Renate Kunert,et al. Comprehensive Cross-Clade Neutralization Analysis of a Panel of Anti-Human Immunodeficiency Virus Type 1 Monoclonal Antibodies , 2004, Journal of Virology.
[24] John P. Moore,et al. Urgently needed: a filter for the HIV-1 vaccine pipeline , 2004, Nature Medicine.
[25] John P. Moore,et al. The CCR5 and CXCR4 coreceptors--central to understanding the transmission and pathogenesis of human immunodeficiency virus type 1 infection. , 2004, AIDS research and human retroviruses.
[26] Michael Greenberg,et al. Enfuvirtide: the first therapy to inhibit the entry of HIV-1 into host CD4 lymphocytes , 2004, Nature Reviews Drug Discovery.
[27] Wayne C Koff,et al. HIV vaccine design and the neutralizing antibody problem , 2004, Nature Immunology.
[28] Olson Wc,et al. Resistance to HIV-1 entry inhibitors. , 2003 .
[29] B. Cullen,et al. Inhibition of Human Immunodeficiency Virus Type 1 Replication in Primary Macrophages by Using Tat- or CCR5-Specific Small Interfering RNAs Expressed from a Lentivirus Vector , 2003, Journal of Virology.
[30] John P. Moore,et al. Inhibiting sexual transmission of HIV-1 infection , 2003, Nature Reviews Microbiology.
[31] N. Meanwell,et al. Biochemical and Genetic Characterizations of a Novel Human Immunodeficiency Virus Type 1 Inhibitor That Blocks gp120-CD4 Interactions , 2003, Journal of Virology.
[32] S. A. Gallo,et al. The HIV Env-mediated fusion reaction. , 2003, Biochimica et biophysica acta.
[33] Lynn Morris,et al. The CCR5 and CXCR4 Coreceptors Are Both Used by Human Immunodeficiency Virus Type 1 Primary Isolates from Subtype C , 2003, Journal of Virology.
[34] John P. Moore,et al. Entry inhibitors SCH-C, RANTES, and T-20 block HIV type 1 replication in multiple cell types. , 2003, AIDS research and human retroviruses.
[35] John P. Moore,et al. Human Immunodeficiency Virus Type 1 Attachment, Coreceptor, and Fusion Inhibitors Are Active against both Direct and trans Infection of Primary Cells , 2003, Journal of Virology.
[36] Q. Sattentau,et al. Occupancy and mechanism in antibody-mediated neutralization of animal viruses. , 2002, The Journal of general virology.
[37] Martin S. Hirsch,et al. Anti-Human Immunodeficiency Virus Interactions of SCH-C (SCH 351125), a CCR5 Antagonist, with Other Antiretroviral Agents In Vitro , 2002, Antimicrobial Agents and Chemotherapy.
[38] Bette T. Korber,et al. Immune control of HIV: the obstacles of HLA and viral diversity , 2001, Nature Immunology.
[39] A. Trkola,et al. Potent, Broad-Spectrum Inhibition of Human Immunodeficiency Virus Type 1 by the CCR5 Monoclonal Antibody PRO 140 , 2001, Journal of Virology.
[40] D. Burton,et al. Antibody and virus: binding and neutralization. , 2000, Virology.
[41] John P. Moore,et al. Will Multiple Coreceptors Need To Be Targeted by Inhibitors of Human Immunodeficiency Virus Type 1 Entry? , 1999, Journal of Virology.
[42] Dan R. Littman,et al. Use of Coreceptors Other Than CCR5 by Non-Syncytium-Inducing Adult and Pediatric Isolates of Human Immunodeficiency Virus Type 1 Is Rare In Vitro , 1998, Journal of Virology.
[43] A. Trkola,et al. Neutralization Sensitivity of Human Immunodeficiency Virus Type 1 Primary Isolates to Antibodies and CD4-Based Reagents Is Independent of Coreceptor Usage , 1998, Journal of Virology.
[44] A. Trkola,et al. Human immunodeficiency virus type 1 strains of subtypes B and E replicate in cutaneous dendritic cell-T-cell mixtures without displaying subtype-specific tropism , 1997, Journal of virology.
[45] K. Mayer,et al. Microbicides to prevent HIV transmission: overcoming obstacles to chemical barrier protection. , 2006, The Journal of infectious diseases.
[46] F. McCutchan,et al. Global epidemiology of HIV , 2006, Journal of medical virology.
[47] S. Hammer,et al. Treatment for adult HIV infection: 2004 recommendations of the International AIDS Society-USA Panel. , 2004, JAMA.
[48] W. Olson,et al. Resistance to HIV-1 entry inhibitors. , 2003, Current drug targets. Infectious disorders.